Dr John Buscombe

British Nuclear Medicine Society

Dr John Buscombe is the President of the British Nuclear Medicine Society and works as a Consultant Physician in Nuclear Medicine in Cambridge.

dont miss

Theranostics in prostate cancer new or false dawn

Over the past 2 years new imaging and therapeutic options using radiolabelled prostate specific membrane antigen have been developed which enable us to see disease which cannot be found by other methods with gallium-68 PSMA PET-CT. Newer work has linked this to targeted radionuclide therapy using beta and alpha emitter labelled PSMA is previously untreatable metastatic prostate cancer which is being actively developed.

EVEN MORE SEMINARS

  • Estevao Mauricio Bagi: Speaking at the European Neurological Convention

    Estevao Mauricio Bagi
    Royal Brompton & Harefield Hospitals Specialist Care

    Cardiac PET-CT : Rubidium-82 Myocardium Perfusion & 18F-FDG Cardiac Sarcoidosis

  • Dr Sam Hare: Speaking at the European Neurological Convention

    Dr Sam Hare
    Royal Free London NHS Foundation Trust

    How I evaluate lung lesions for CT-guided biopsy?

  • Dr Arjun Nair: Speaking at the European Neurological Convention

    Dr Arjun Nair
    The Harley Street Clinic (Part of HCA healthcare UK)

    Advance Technologies in Diagnostics

  • Glenn Flux: Speaking at the European Neurological Convention

    Glenn Flux
    Royal Marsden / Institute of Cancer Research

    The emergence and resurgence of radiotherapeutics for cancer treatment

  • Mohamed Torky: Speaking at the European Neurological Convention

    Mohamed Torky
    Hospital Germans Trias i pujol. Barcelona. Spain

    The seminar will present the preliminary results of a study included patients with peripheral lung lesions suspicious for lung cancer. Trans-bronchial